News Releases

Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.

Get News Alerts by Email

Aug 31, 2017

Astellas to Present New Data for Enzalutamide and IMAB362 at 2017 European Society of Medical Oncology (ESMO) Annual Meeting
Aug 21, 2017

First Patient Dosed in Phase 3 MORPHO Trial Evaluating Gilteritinib as Maintenance Therapy Following Hematopoietic Stem Cell Transplant in Patients with FLT3 Mutation-positive Acute Myeloid Leukemia
Aug 2, 2017

Astellas Announces Leadership Changes in Corporate Affairs Organization

Moyra Knight, Andrew Lewis and Karl Uhlendorf named to key roles
- Photos 3
Jul 28, 2017

Astellas Reports First Quarter FY2017 Financial Results
Jul 26, 2017

Astellas Announces Wind-Down of Agensys Research Operations

Astellas to Retain Certain Promising Antibody-Drug Conjugate R&D Programs of Agensys
Jul 20, 2017

U.S. FDA Grants Orphan-Drug Designation to Astellas for Development of FLT3 Inhibitor Gilteritinib in Acute Myeloid Leukemia
Jul 19, 2017

Astellas Farma Brasil named a top-ten pharmaceutical company to work for in Brazil

Astellas recognized by Great Place to Work® Institute
- Photos 1
Jul 17, 2017

Astellas Commitment to Creating Sustainable Community Impact Highlighted in Americas Corporate Social Responsibility Report Card 2016
- Photos 1
Jul 13, 2017

Astellas Head of Medical Affairs Americas Shontelle Dodson Joins National Pharmaceutical Council Board of Directors
- Photos 1
Jul 12, 2017

Astellas Announces Leadership Changes in US Commercial Organization

David Musselman and Lynn Gerber named to key regional sales roles
- Photos 3

Show per page